This month’s people on the move includes a new therapeutic lead at Advanced Clinical, with plans to create a network of investigation sites, as well as CEOs at AIT Bioscience and Pharm-Olam, who discuss plans for moving forward.
Escient Pharmaceuticals has entered the market after closing a $40m Series A financing round – and has contacted Eurofins Discovery for integrated drug discovery services.
The online marketplace for outsourced research has expanded its compliance solution to include animal welfare – and is working with customers to increase transparency and educate researchers.
Pepticom’s technology aims to ‘vastly reduce’ risk of failure in peptide drug candidates’ discovery and development, by utilizing artificial intelligence models.
GE Healthcare opens lab space to provide developers with access to protein and cell analysis technologies to encourage networking and partnering on R&D services.
The research models and services provider has acquired a company that specializes in tissue collections, and hematology, and immunology cell isolations to help meet its ‘ever-increasing’ client needs.
Organ-on-a-chip systems are poised to revolutionize drug development in many ways, say researchers advancing the technology, which could support gender-specific medicine, among other use cases.
Charles River Laboratories recently announced that Alzheimer’s Research UK selected the company to join the Dementia Consortium to help researchers progress projects to in vivo proof of concept.
N4 Pharma creates DNA and RNA transfection technology using silica nanoparticles with an irregular surface, which traps and protects nucleic acid during its journey to cells.
GSK taps Lyell’s technology to delay ‘exhaustion’ of T cells and will explore creating a new platform to develop cell and gene therapies for rare cancers.
Insilico Medicine will use its next-generation AI platform to accelerate CRFH’s drug discovery and development efforts – a deal that exemplifies maturation in the market as researchers explore new ways to conduct R&D.
A partnership between Sciex and Protein Metrics aims to make their services compatible with other software services available, enabling drug developers to work in an ‘open ecosystem.’
CAS collates the world’s largest collection of formulations – a ‘one-stop-shop’ that will help formulators innovate faster and solve problems, ultimately reducing drug development timelines, says project lead.
SEngine Precision Medicine raises $5.1m in a Series A investment round to further develop its 3D tumor organoid diagnostic and drug discovery platform.
In Vivo Research Services has developed a 3D visualization technology that provides direct imaging data in real-time, aiming to reduce drug development time and costs.
SEngine Precision Medicine and Atomwise recently announced a new joint venture through which the companies aim to ‘speed and streamline’ new drug discovery, says CEO.
A-Alpha Bio raises $2.8m from venture capital firms and angel investors to further develop its technology – and initiate drug discovery and optimization partnerships with pharmaceutical companies.
PPD is expanding its immunochemistry and biomarker space by 8,000 square feet, the addition of which will also support a dedicated team for one of the company’s global biopharmaceutical clients.
Insilico Medicine brings in $37m to further develop its artificial intelligence work after publishing a study that demonstrates the ‘real-world potential’ of AI for drug discovery – moving the idea from theory to reality.
There has been a lot of discussion surrounding the use of artificial intelligence in drug development – with several deals, alliances, and partnerships made so far this year. Here, Outsourcing-Pharma takes a look back at some of these announcements, as...
The drug discovery and preclinical services company has moved its US office to Kendall Square as it looks to ‘sustainably grow’ its US presence and increase sales in the coming years, says SVP.
Increasingly complex clinical trials are putting pressure on CROs to expand their service offerings in what has been a historically monolithic space – with diagnostics also continuing to play a more important role in the market, says industry expert.
The last month of summer saw several hires, including a lead for Worldwide Clinical Trials’ Japan operations, CEO appointments at CordenPharma and LabConnect, and Altasciences’ new CSO, who joins the company from Syneos.
908 Devices launches Rebel, a bioprocess analyzer, enabling researchers to conduct their own cell culture media analysis to accelerate process development ‘by weeks’.
NHS GDE Trust Worcestershire Health and Care collaborates with Clinithink to better manage its clinical data through the latter’s ‘natural language processing’ platform.
Researchers develop organ-on-an-electronic-chip platform to explore the electrophysiology of iPSC-derived cardiomyocytes and understand how the heart communicates.
Themis obtains an exclusive licence from Merck to develop vaccine candidates with an undisclosed indication, using its measles virus vector-based platform.
As summer heated up, the pharmaceutical industry saw major developments in preclinical models from new software to 3D-printed tissue, all in the name of drug development.
Researchers show miniature livers can develop steatohepatitis and fibrosis, pointing to potential for personalized hepatic drug discovery and toxicity platforms.
Schrödinger secures further funding, extends collaboration with Morphic Therapeutic on computational discovery platform for oral integrin drugs for the second time.
Engineered cardiac tissues generated using Tara Biosystems' heart-on-a-chip system predict how patients will respond to a range of drugs, as demonstrated in a recent study with GSK.
SGS’ OneVision initiative is working to standardize record-keeping across the global life sciences industry in an aim to accelerate laboratory testing, development, and eliminate paper-based systems.
Boehringer Ingelheim and the University of Texas MD Anderson Cancer Center entered a multi-year partnership to conduct collaborative translational research for lung and GI cancers.
Prellis advances its goal of using 3D holographic printing to create organoids for research and development – recently closing a $10.5m investment round to further develop its technology, which accelerates drug screening, says CEO.
Takeda and Sosei both have a proud heritage in Japan and recently entered a billion-dollar partnership with Sosei to discover, develop, and commercialize molecules for patients in need around the world.
Caprion Biosciences and HistoGeneX join forces, combining the two businesses to provide a source for immune monitoring, protein characterization, and tissue pathology solutions, as immunotherapy landscape evolves.
CordenPharma has a new CEO, Arbour Group advances plans to expand in RTP, Ashfield brings on a former Iqvia VP, and Recursion adds to its c-suite after raising $121m this month.
Aiming to speed up and facilitate the clinical development of liver failure treatments, Taconic launches the first commercially available diet-induced NASH rodent model.
Rosalind Franklin University of Medicine and Science opens its incubator, Helix 51, creating wet lab and research space for the Illinois bioscience hub.
A study by Biofourmis aims to improve patient centricity in the drug approval processes by using wearable technology and mobile software to monitor the quality of life for patients with heart failure.
